Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer

Published:2020 Issue:4 Volume:43 Page:153-159
ISSN:2296-5270
Container-title:Oncology Research and Treatment
language:en
Short-container-title:Oncol Res Treat

Author:

Wu Qiuji,Wang Xinyuan,Zhang Mengxi,Liao Weiting,Wang Feng,Li Qiu

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,Hematology

Reference19 articles.

1. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011 Oct;378(9801):1461–84.

2. Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, et al. Breast cancer in China. Lancet Oncol. 2014 Jun;15(7):e279–89.

3. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May;365(9472):1687–717.

4. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010 Jul;28(20):3271–7.

5. Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep;22 Suppl 6:vi25–30.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review;BMJ Global Health;2023-11

2. Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review;The Oncologist;2021-06-05

3. The anti‐adhesive effect of anti‐VEGF agents in experimental models: A systematic review;Wound Repair and Regeneration;2020-12-14

4. MEX3A promotes triple negative breast cancer proliferation and migration via the PI3K/AKT signaling pathway;Experimental Cell Research;2020-10

5. Bevacizumab plus paclitaxel not cost effective for HER2− MBC;PharmacoEconomics & Outcomes News;2020-04